Mads Haugland Haugen (Mads H Haugen)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 7

Top Topics

Dna Damage Response

Epidermal Growth Factor Receptor

Neoadjuvant Chemotherapy

Top Venues

Molecular oncology

Cancer research communications

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Thomas Fleischer, Mads Haugland Haugen, Jørgen Ankill, Laxmi Silwal-Pandit, Anne-Lise Børresen-Dale, Ingrid Hedenfalk, Thomas Hatschek, Jörg Tost, Olav Engebraaten, Vessela N Kristensen
An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer. Molecular oncology 18 (8) (2024)
Thomas Fleischer, Mads Haugland Haugen, Jørgen Ankill, Laxmi Silwal-Pandit, Anne-Lise Børresen-Dale, Ingrid Hedenfalk, Thomas Hatschek, Jörg Tost, Olav Engebraaten, Vessela N Kristensen
An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer. Molecular oncology (2024)
Thomas Fleischer, Mads Haugland Haugen, Jørgen Ankill, Laxmi Silwal-Pandit, Anne-Lise Børresen-Dale, Ingrid Hedenfalk, Thomas Hatschek, Jörg Tost, Olav Engebraaten, Vessela N Kristensen
An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer. Molecular oncology 18 (8) (2024)
Thomas Fleischer, Mads Haugland Haugen, Jørgen Ankill, Laxmi Silwal-Pandit, Anne-Lise Børresen-Dale, Ingrid Hedenfalk, Thomas Hatschek, Jörg Tost, Olav Engebraaten, Vessela N Kristensen
An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer. Molecular oncology 18 (8) (2024)
Vigdis Nygaard, Anne Hansen Ree, Vegar Johansen Dagenborg, Anne-Lise Børresen-Dale, Bjørn Edwin, Åsmund Avdem Fretland, Krzysztof Grzyb, Mads Haugland Haugen, Gunhild Mari Mælandsmo, Norman John Carr
A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases. Cancer research communications 3 (2) (2023)
Vigdis Nygaard, Anne Hansen Ree, Vegar Johansen Dagenborg, Anne-Lise Børresen-Dale, Bjørn Edwin, Åsmund Avdem Fretland, Krzysztof Grzyb, Mads Haugland Haugen, Gunhild Mari Mælandsmo, Norman John Carr
A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases. Cancer research communications 3 (2) (2023)
Karine Flem-Karlsen, Erin McFadden, Nasrin Omar, Mads Haugland Haugen, Geir Frode Øy, Truls Ryder, Hans Petter Gullestad, Robert Hermann, Gunhild Mari Mælandsmo, Vivi Ann Flørenes
Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma. Molecular cancer therapeutics 19 (3) (2019)